FREDERICK, Md., Sept. 10 /PRNewswire-FirstCall/ -- BioElectronics Corporation (BIEL) announced today that it has appointed Abdulkader Al-Mehyar Moh’d Basheer Halawy as sales agent and distributor in the Middle Eastern region. The company launched the new sales program with orders for 20,000 units.
“These are significant initial orders for BioElectronics Corporation showing that this region has a strong demand for drug-free medical products,” said Andrew J. Whelan, CEO of BioElectronics Corporation. “There is well established need for drug free anti inflammatory therapy in the Middle East which we expect to capture and expand.”
Whelan explained that Dr. Halawy has had significant sales management and training experience at Pfizer and several other leading pharmaceutical companies. As demonstrated by his initial launch, Dr. Halawy has developed an extensive network of contacts throughout the region. He will be located in Riyadh, and will be responsible for sales throughout the region.
BioElectronics Corporation is the maker of inexpensive, drug-free, anti-inflammatory medical devices and patches. The Company’s inexpensive wafer thin patches and devices contain an embedded microchip and battery that deliver pulsed electromagnetic energy, a clinically proven and widely accepted anti-inflammatory and pain relief therapy that heretofore has only been possible to obtain from large, facility-based equipment. BioElectronics markets and sells its current products under the brand names ActiPatch(TM) and RecoveryRx(TM). The dermal patch delivery system creates a multitude of new product opportunities for chronic and acute inflammatory conditions.
For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.
Information on ActiPatch and BioElectronics Corporation is available at the following websites:
Safe Harbor Statement
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.
CONTACT: Kelly Lorenz of BioElectronics Corporation, +1-866-757-2284 ext
101, +1-301-874-4890 ext 101, (fax) +1-301-874-6935
Web site: http://www.bioelectronicscorp.com/
